- Current report filing (8-K)
08 Août 2012 - 11:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 8, 2012
BIOSCRIP, INC.
(Exact name of Registrant as specified
in its charter)
Delaware
|
|
0-28740
|
|
05-0489664
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
100 Clearbrook Road, Elmsford, New York
|
|
10523
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code:
(914) 460-1600
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On August 8, 2012, BioScrip, Inc. (the “Company”)
issued a press release reporting its 2012 second quarter financial results. A copy of the press release is furnished with this
Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
As previously announced, the Company will host a
conference call to discuss its second quarter 2012 financial results on August 9, 2012 at 9:00 a.m. Eastern Time. Interested
parties may participate in the conference call by dialing 800-750-5857 (US), or 212-231-2921 (International), 5 to 10 minutes
prior to the start of the call. A replay of the conference call will be available for two weeks after the call's completion
by dialing 800-633-8284 (US) or 402-977-9140 (International) and entering conference call ID number 21600696. An audio
webcast and archive will also be available under the “Investor Relations” section of the Company’s website
at www.bioscrip.com for a period of 30 days following the conference call.
The press release includes certain non-GAAP financial measures
as described therein. As required by Regulation G, reconciliation between any non-GAAP financial measures presented and the most
directly comparable GAAP financial measures is also provided.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits. See the Exhibit Index which is hereby incorporated
by reference.
As provided in General Instruction B.2 to Form 8-K, the information
furnished in Item 2.02 and in Exhibit 99.1 hereto as it relates to the Company’s financial results for the quarter and six
months ended June 30, 2012, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities under that Section and shall not be deemed incorporated by reference
into any filing of the Company with the Securities and Exchange Commission under the Securities Act of 1933 or the Exchange Act,
except as shall be expressly provided by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
Date: August 8, 2012
|
By:
|
/s/ Kimberlee C. Seah
|
|
|
Kimberlee C. Seah
|
|
|
Senior Vice President and General Counsel
|
Exhibit
Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
BioScrip, Inc. press release dated August 8, 2012.
|
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024